KRTL BioTech

Op-ed: Don't reject the 60/40 portfolio. Embrace it

Op-ed: Don't reject the 60/40 portfolio. Embrace it

Amid unique geopolitical and financial circumstances that are hammering stock markets, some are questioning the traditional 60/40 stocks/bonds investment model.